PDF file: 441-2487_VAED_ADE.pdf
OPQ ID: 441-2487
Session: 441
Question number: Q-2487
Sessional paper: Q-2487
Title: VAED -ADE
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC, PHAC, NACI
Date asked: 2024-03-21
Date tabled: 
Submitted by: Mr. Dalton (Pitt Meadows—Maple Ridge)
Reply by: Minister of Health
Responded by: Mr. Yasir Naqvi
Pages: 4
Status: not processed
Alert: yellow
Questions asked: 8
Questions answered: 7
Percent responded: 88%
Referenced sources: Canada.ca, COVID-19 vaccines and treatments portal
Referenced links: https://covid-vaccine.canada.ca/info/SBD00510-comirnaty-en.html, https://covid-vaccine.canada.ca/info/SBD00511-spikevax-en.html, https://covid-vaccine.canada.ca/info/SBD00581-nuvaxovid-en.html, https://covid-vaccine.canada.ca/info/SBD00519-vaxzevria-en.html, https://covid-vaccine.canada.ca/info/SBD00522-jcovden-en.html, https://covid-vaccine.canada.ca/info/SBD00582-covifenz-en.html
Official link: https://www.google.com/search?q=Q-2487+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2487_VAED_ADE.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2487.txt
Original filename: Q-2487_HC, VAED  -ADE.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2487_HC, VAED  -ADE.pdf
Machine extracted at: 2026-06-30 12:58:27

References / links:
- https://covid-vaccine.canada.ca/info/SBD00510-comirnaty-en.html
- https://covid-vaccine.canada.ca/info/SBD00511-spikevax-en.html
- https://covid-vaccine.canada.ca/info/SBD00581-nuvaxovid-en.html
- https://covid-vaccine.canada.ca/info/SBD00519-vaxzevria-en.html
- https://covid-vaccine.canada.ca/info/SBD00522-jcovden-en.html
- https://covid-vaccine.canada.ca/info/SBD00582-covifenz-en.html
- Canada.ca
- COVID-19 vaccines and treatments portal

Machine notes:
(none)

Question text preview:
With regard to Health Canada's (HC) authorization of COVID-19 vaccines: (a) has HC received studies about theoretical risk of VaccineAssociated Enhanced Disease (VAED), also referred to as Antibody-Dependent Enhancement (ADE), from the manufacturers of the COVID19 vaccines;
(b) if the answer to (a) is affirmative, (i) what were the outcome of the studies, (ii) which manufacturers and independent researchers are conducting these studies, (iii) what were the timelines to completion;
(c) if the answer to (a) is negative, did HC, the Public
Health Agency of Canada, or the National Advisory Committee identify a need for long-term studies to examine VAED, and, if not, why not;
(d) has any federal health agency, department or other government entity been monitoring for VAED ADE post-COVID-19 injections;
(e) if the answer to (d) is affirmative, (i) what is the data, (ii) what are the timelines, (iii) was this active or passive monitoring;
(f) if the answer to
(d) is negative, why not; and (g) has any federal health agency, department or other government entity been monitoring for the potential of vaccine-enhanced infectivity?